TOP TEN perturbations for 1553326_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553326_at
Selected probe(set): 1553326_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553326_at (1553326_at) across 6672 perturbations tested by GENEVESTIGATOR:

rheumatoid arthritis study 37 (mono; CD14+ CD16+) / rheumatoid arthritis study 37 (mono; CD14+ CD16-)

Relative Expression (log2-ratio):-0.803658
Number of Samples:6 / 6
Experimental rheumatoid arthritis study 37 (mono; CD14+ CD16+)
Peripheral blood CD14+ CD16+ monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00±19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81±2.02 mg/dl; ESR 83.67±46.21 mm/hr; DAS28-CRP 5.06±1.22; DAS28-ESR 5.92±1.50; SDAI 28.76±19.03; CDAI 25.95±18.08; HAQ-DI 1.02±0.95; TJC28 8.17±6.4; SJC28 7.50±7.66; Pain, VAS 52.67±20.20; Physician GA, VAS 46.83 ±29.30 mm; Subject GA, VAS 56.00±17.61 mm
Control rheumatoid arthritis study 37 (mono; CD14+ CD16-)
Peripheral blood CD14+ CD16- monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00±19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81±2.02 mg/dl; ESR 83.67±46.21 mm/hr; DAS28-CRP 5.06±1.22; DAS28-ESR 5.92±1.50; SDAI 28.76±19.03; CDAI 25.95±18.08; HAQ-DI 1.02±0.95; TJC28 8.17±6.4; SJC28 7.50±7.66; Pain, VAS 52.67±20.20; Physician GA, VAS 46.83 ±29.30 mm; Subject GA, VAS 56.00±17.61 mm

medulloblastoma study 2 / non-tumor brain tissue

Relative Expression (log2-ratio):0.73823214
Number of Samples:4 / 9
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):-0.71464396
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

LPS study 6 / vehicle (saline) treated alveolar macrophage cell sample

Relative Expression (log2-ratio):-0.68752
Number of Samples:6 / 6
Experimental LPS study 6
Alveolar macrophages obtained from contralateral lung segment of healthy volunteer exposed to LPS (4 ng/kg body weight) for 6 hours. LPS from Escherichia coli (diluted in 10 ml saline) was instilled into the contralateral lung by video bronchoscope. 6 hours after LPS challenge bronchoalveolar lavage was performed by rinsing the lungs 7 times with 20 ml prewarmed 0.9% saline (after instillation saline was immediately aspirated). Alveolar macrophages (CD71+ cells) were isolated from bronchoalveolar lavage fluid (BALF) using CD71 microbeads. Volunteers were all men, non-smokers and physically healthy (tested by physical examination, blood and urine investigation, electrocardiogram and spirometry). ATC code:---
Control vehicle (saline) treated alveolar macrophage cell sample
Alveolar macrophages obtained from contralateral lung segment of healthy volunteer exposed to saline for 6 hours. Saline (10 ml) was instilled into the contralateral lung by video bronchoscope. 6 hours after vehicle challenge bronchoalveolar lavage was performed by rinsing the lungs 7 times with 20 ml prewarmed 0.9% saline (after instillation saline was immediately aspirated). Alveolar macrophages (CD71+ cells) were isolated from bronchoalveolar lavage fluid (BALF) using CD71 microbeads. Volunteers were all men, non-smokers and physically healthy (tested by physical examination, blood and urine investigation, electrocardiogram and spirometry).

systemic onset JIA study 6 (baseline; placebo) / normal blood sample

Relative Expression (log2-ratio):0.68262863
Number of Samples:22 / 22
Experimental systemic onset JIA study 6 (baseline; placebo)
Whole blood samples collected from systemic juvenile idiopathic arthritis patients at baseline (day 1), prior to placebo treatment. Patients were 2 to 19 years of age with a confirmed diagnosis of febrile SJIA with high disease activity. aACR response was scored at day 15. Concomitant therapy with a prednisone equivalent (up to 1.0 mg/kg/day) and stable doses of nonsteroidal anti inflammatory drugs and methotrexate (≤20 mg/m2 per week) were permitted.
Control normal blood sample
Whole blood samples collected from healthy volunteers.

systemic lupus erythematosus study 14 (neutrophil) / normal neutrophil sample

Relative Expression (log2-ratio):-0.58958864
Number of Samples:10 / 9
Experimental systemic lupus erythematosus study 14 (neutrophil)
Neutrophil samples isolated from patients with systemic lupus erythematosus (SLE). Patients fulfilled the revised American College of Rheumatology criteria for SLE and disease activity was quantified by SLEDAI. Dextran sedimentation of red blood cell pellets was used for normal-density neutrophils isolation. Purity was at least 95%.
Control normal neutrophil sample
Neutrophil samples isolated from healthy subjects. Dextran sedimentation of red blood cell pellets was used for normal-density neutrophils isolation. Purity was at least 95%.

epigallocatechin gallate study 1 (45840ng/ml) / vehicle (DME) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):0.5871124
Number of Samples:3 / 17
Experimental epigallocatechin gallate study 1 (45840ng/ml)
Bronchial epithelial cells (NHBE) treated with epigallocatechin gallate (45840ng/ml; vendor: Santa Cruz / catalog number: sc-200802 / catalog name: (-)-Epigallocatechin Gallate) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). ATC code:---
Control vehicle (DME) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial).

medulloblastoma study 2 / medulloblastoma study 1

Relative Expression (log2-ratio):0.582325
Number of Samples:4 / 17
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control medulloblastoma study 1
Primary tumor tissue sample from the infratentorial brain of pediatric patients with classical medulloblastoma.

SARS-CoV study 4 (48h) / uninfected Calu-3 2B4 cell sample (48h)

Relative Expression (log2-ratio):0.5697508
Number of Samples:3 / 3
Experimental SARS-CoV study 4 (48h)
Human 2B4 cells, a clonal derivative of Calu3 cell line (originated from a human pulmonary adenocarcinoma) were infected with 0.1 MOI of SARS-CoV (Urbani strain) for 48 hours.
Control uninfected Calu-3 2B4 cell sample (48h)
Human 2B4 cells, a clonal derivative of Calu3 cell line that remained uninfected for 48 hours.

dupilumab study 1 (150mg; non-lesional) / atopic dermatitis study 9 (baseline; non-lesional)

Relative Expression (log2-ratio):0.5579052
Number of Samples:2 / 7
Experimental dupilumab study 1 (150mg; non-lesional)
Non-lesional skin tissue biopsies from patients with moderate-severe chronic atopic dermatitis obtained after therapy with dupilumab (150mg / wk / 4wks). 150mg of dupilumab was given once a week as subcutaneous injection, 4 injections in total. The samples were obtained 1 week after the last dupilumab injection. Dupilumab is an anti IL-4R mAb. ATC code:---
Control atopic dermatitis study 9 (baseline; non-lesional)
Non-lesional skin tissue biopsies from patients with moderate-severe chronic atopic dermatitis obtained before therapy with dupilumab (150mg / wk / 4wks).